304 related articles for article (PubMed ID: 33710277)
1. Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants.
Peters EN; Mosesova I; MacNair L; Vandrey R; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
J Anal Toxicol; 2022 Apr; 46(4):393-407. PubMed ID: 33710277
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.
Peters EN; Mosesova I; MacNair L; Vandrey R; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
J Anal Toxicol; 2022 May; 46(5):528-539. PubMed ID: 33848338
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of escalating cannabinoid doses in healthy cats.
Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
[No Abstract] [Full Text] [Related]
8. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
9. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
Stott CG; White L; Wright S; Wilbraham D; Guy GW
Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
[TBL] [Abstract][Full Text] [Related]
10. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study.
Bonomo Y; Norman A; Collins L; O'Neill H; Galettis P; Trinca J; Strauss N; Martin J; Castle D
Pain Ther; 2022 Mar; 11(1):171-189. PubMed ID: 34921662
[TBL] [Abstract][Full Text] [Related]
12. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.
Bergeria CL; Spindle TR; Cone EJ; Sholler D; Goffi E; Mitchell JM; Winecker RE; Bigelow GE; Flegel R; Vandrey R
J Anal Toxicol; 2022 Jul; 46(6):583-591. PubMed ID: 35438179
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of five distinct commercially available hemp-derived topical cannabidiol products.
Zamarripa CA; Tilton HE; Lin S; Cone EJ; Winecker RE; Flegel RR; Kuntz D; Beals M; Jacques M; Clark M; Welsh ER; Wagner L; Bonn-Miller MO; Vandrey R; Spindle TR
J Anal Toxicol; 2024 Mar; 48(2):81-98. PubMed ID: 38217086
[TBL] [Abstract][Full Text] [Related]
15. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial.
Hansen JS; Boix F; Hasselstrøm JB; Sørensen LK; Kjolby M; Gustavsen S; Hansen RM; Petersen T; Sellebjerg F; Kasch H; Rasmussen PV; Finnerup NB; Saedder EA; Svendsen KB
Clin Transl Sci; 2024 Jan; 17(1):e13685. PubMed ID: 38054364
[TBL] [Abstract][Full Text] [Related]
17. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
18. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis".
Pacifici R; Pichini S; Pellegrini M; Rotolo MC; Giorgetti R; Tagliabracci A; Busardò FP; Huestis MA
Clin Chem Lab Med; 2020 Apr; 58(5):682-689. PubMed ID: 30956228
[TBL] [Abstract][Full Text] [Related]
19. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
20. Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs.
Vaughn D; Kulpa J; Paulionis L
Front Vet Sci; 2020; 7():51. PubMed ID: 32118071
[No Abstract] [Full Text] [Related]
[Next] [New Search]